

## NEWS

### **BENITEC ANNOUNCES APPOINTMENT OF COMPANY SECRETARY AND CHANGE OF REGISTERED ADDRESS**

**February 23, 2006, Mountain View, California** – Benitec Ltd. (ASX: BLT), a leading developer of RNA interference (RNAi)-based therapeutics, announced today that Ray Iacono has been appointed Company Secretary.

Mr. Iacono is a Fellow Certified Practicing Accountant Australia, a Fellow of the Taxation Institute of Australia, and a Tax Agent. He is also the principal and CEO of Adsto International Pty Ltd. Adsto specializes in assisting foreign companies in establishing operations in Australia and Europe and attending to the administrative, fiscal, statutory, secretarial, and reporting requirements for those companies. Adsto has been providing accounting and tax services to Benitec since 2005. Mr. Iacono has served as a Director for several non-listed companies, and he served as a Non-executive Director of Benitec from 2000 to 2002. He also previously served as Managing Director and CEO of Olivetti Australia Pty Ltd and Managing Director and CEO of TA Triumph Adler Australia Pty Ltd.

Benitec's registered office is now at the following address:

Benitec Limited  
C/- Adsto International  
Adsto House  
401 New Canterbury Road  
P.O. Box 20  
Dulwich Hill, NSW, Australia 2203

Phone: +61 2 9560 1110

Fax: +61 2 9388 7313

### **About Benitec**

Benitec is an international biotechnology company focused on developing therapeutics to treat serious diseases using its proprietary RNAi technology. Benitec is listed on the Australian Stock Exchange and has its operations in Mountain View, California, USA. Its lead therapeutic programs are for Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles,

California, will enter Phase I clinical trials in 2006. Benitec's RNAi therapeutic for HCV will enter clinical trials in 2007. For additional information, please visit [www.benitec.com](http://www.benitec.com).

### **Forward-looking Statements**

*This press release contains forward-looking statements that reflect the Companies' current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Companies' research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.*

### **CONTACTS:**

#### **BENITEC LTD.**

Laurie Reisinger

+1 650 564 9850 ext.1101

[lreisinger@benitec.com](mailto:lreisinger@benitec.com)